文献速递心脑血管急症

齐贝西兰 RNA 干扰治疗轻中度高血压:KARDIA-1 随机临床试验

RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01
一句话结论轻中度高血压患者皮下注射齐贝西兰 150–600 mg、每 3 或 6 个月一次,3 个月时 24 小时动态收缩压较安慰剂显著降低 14.1–16.7 mm Hg。

KARDIA-1 为 2 期、随机、双盲、剂量探索研究,在 4 个国家 78 个中心纳入 394 例轻中度高血压成人(洗脱后日间动态收缩压 135–160 mm Hg),随机接受齐贝西兰 150 mg、300 mg 或 600 mg 每 6 个月一次,或 300 mg 每 3 个月一次,或安慰剂每 3 个月一次,共 6 个月。主要终点为基线至第 3 个月 24 小时动态收缩压最小二乘均值变化组间差异。齐贝西兰各剂量组较安慰剂降低 14.1–16.7 mm Hg(P < .001)。6 个月内齐贝西兰组不良事件 60.9% vs 安慰剂 50.7%,严重不良事件 3.6% vs 6.7%,药物相关非严重不良事件 16.9% vs 8.0%(主要为注射部位反应和轻度高钾血症)。

要点

  • 第 3 个月 24 小时动态收缩压较基线变化:齐贝西兰 150 mg 每 6 个月组 -7.3 mm Hg(95%CI -10.3 至 -4.4),300 mg 每 3 或 6 个月组 -10.0 mm Hg(95%CI -12.0 至 -7.9),600 mg 每 6 个月组 -8.9 mm Hg(95%CI -11.9 至 -6.0),安慰剂组 +6.8 mm Hg(95%CI 3.6 至 9
  • 第 3 个月 24 小时动态收缩压变化组间差异 vs 安慰剂:150 mg 每 6 个月组 -14.1 mm Hg(95%CI -19.2 至 -9.0;P < .001),300 mg 每 3 或 6 个月组 -16.7 mm Hg(95%CI -21.2 至 -12.3;P < .001),600 mg 每 6 个月组 -15.7 mm Hg(95%CI -20.8 至 -10.6;
  • 6 个月内齐贝西兰组不良事件 60.9% vs 安慰剂组 50.7%,严重不良事件 3.6% vs 6.7%。
  • 药物相关非严重不良事件齐贝西兰组 16.9%(主要为注射部位反应和轻度高钾血症)vs 安慰剂组 8.0%。

适用人群与场景

  • 成人轻中度高血压,定义为抗高血压药物洗脱后日间平均动态收缩压 135–160 mm Hg。
  • 研究在 4 个国家 78 个中心开展,纳入 394 例随机患者,全分析集 377 例(齐贝西兰 302 例,安慰剂 75 例;黑人 93 例 [24.7%];女性 167 例 [44.3%];平均 [SD] 年龄 57 [11] 岁)。

诊断标准与关键阈值

  • 轻中度高血压诊断标准:抗高血压药物洗脱后日间平均动态收缩压 135–160 mm Hg。

处置流程与药物剂量

  • 齐贝西兰皮下注射 150 mg、300 mg 或 600 mg 每 6 个月一次,或 300 mg 每 3 个月一次,共 6 个月;安慰剂每 3 个月一次。

研究设计与关键结果

  • 2 期、随机、双盲、剂量探索研究,78 个中心,4 个国家;394 例随机,全分析集 377 例(齐贝西兰 302 例,安慰剂 75 例)。
  • 主要终点第 3 个月 24 小时动态收缩压最小二乘均值变化组间差异:150 mg 每 6 个月组 -14.1 mm Hg(95%CI -19.2 至 -9.0;P < .001),300 mg 每 3 或 6 个月组 -16.7 mm Hg(95%CI -21.2 至 -12.3;P < .001),600 mg 每 6 个月组 -15.7 mm Hg(95%CI -20.8 至 -10.6;P < .001)。
  • 第 3 个月 24 小时动态收缩压较基线变化:150 mg 每 6 个月组 -7.3 mm Hg(95%CI -10.3 至 -4.4),300 mg 每 3 或 6 个月组 -10.0 mm Hg(95%CI -12.0 至 -7.9),600 mg 每 6 个月组 -8.9 mm Hg(95%CI -11.9 至 -6.0),安慰剂组 +6.8 mm Hg(95%CI 3.6 至 9.9)。
  • 6 个月内齐贝西兰组不良事件 60.9% vs 安慰剂组 50.7%;严重不良事件 3.6% vs 6.7%;药物相关非严重不良事件 16.9%(主要为注射部位反应和轻度高钾血症)vs 8.0%。

证据类型、等级与局限

  • 2 期随机双盲剂量探索研究;原文未报告证据等级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在轻中度高血压成人中,齐贝西兰多个剂量每 3 个月或每 6 个月给药,在第 3 个月显著降低 24 小时动态平均收缩压。

指南或共识出处

  • ClinicalTrials.gov 注册号 NCT04936035。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Angiotensinogen is the most upstream precursor of the renin-angiotensin-aldosterone system, a key pathway in blood pressure (BP) regulation. Zilebesiran, an investigational RNA interference therapeutic, targets hepatic angiotensinogen synthesis.

OBJECTIVE: To evaluate antihypertensive efficacy and safety of different zilebesiran dosing regimens.

DESIGN, SETTING, AND PARTICIPANTS: This phase 2, randomized, double-blind, dose-ranging study of zilebesiran vs placebo was performed at 78 sites across 4 countries. Screening initiation occurred in July 2021 and the last patient visit of the 6-month study occurred in June 2023. Adults with mild to moderate hypertension, defined as daytime mean ambulatory systolic BP (SBP) of 135 to 160 mm Hg following antihypertensive washout, were randomized.

INTERVENTIONS: Randomization to 1 of 4 subcutaneous zilebesiran regimens (150, 300, or 600 mg once every 6 months or 300 mg once every 3 months) or placebo (once every 3 months) for 6 months.

MAIN OUTCOMES AND MEASURES: The primary end point was between-group difference in least-squares mean (LSM) change from baseline to month 3 in 24-hour mean ambulatory SBP.

RESULTS: Of 394 randomized patients, 377 (302 receiving zilebesiran and 75 receiving placebo) comprised the full analysis set (93 Black patients [24.7%]; 167 [44.3%] women; mean [SD] age, 57 [11] years). At 3 months, 24-hour mean ambulatory SBP changes from baseline were -7.3 mm Hg (95% CI, -10.3 to -4.4) with zilebesiran, 150 mg, once every 6 months; -10.0 mm Hg (95% CI, -12.0 to -7.9) with zilebesiran, 300 mg, once every 3 months or every 6 months; -8.9 mm Hg (95% CI, -11.9 to -6.0) with zilebesiran, 600 mg, once every 6 months; and 6.8 mm Hg (95% CI, 3.6-9.9) with placebo. LSM differences vs placebo in change from baseline to month 3 were -14.1 mm Hg (95% CI, -19.2 to -9.0; P < .001) with zilebesiran, 150 mg, once every 6 months; -16.7 mm Hg (95% CI, -21.2 to -12.3; P < .001) with zilebesiran, 300 mg, once every 3 months or every 6 months; and -15.7 mm Hg (95% CI, -20.8 to -10.6; P < .001) with zilebesiran, 600 mg, once every 6 months. Over 6 months, 60.9% of patients receiving zilebesiran had adverse events vs 50.7% patients receiving placebo and 3.6% had serious adverse events vs 6.7% receiving placebo. Nonserious drug-related adverse events occurred in 16.9% of zilebesiran-treated patients (principally injection site reactions and mild hyperkalemia) and 8.0% of placebo-treated patients.

CONCLUSIONS AND RELEVANCE: In adults with mild to moderate hypertension, treatment with zilebesiran across a range of doses at 3-month or 6-month intervals significantly reduced 24-hour mean ambulatory SBP at month 3.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04936035.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Bakris GL, Saxena M, Gupta A, et al. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024. PMID: 38363577. doi:10.1001/jama.2024.0728

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。